HD Immune

Executive Summary

HD Immune is a Vienna-based biotechnology company developing a first-in-class monoclonal antibody therapy for Huntington's disease (HD), a rare and fatal neurodegenerative disorder. Founded in 2018, the company aims to modify disease progression by targeting the toxic mutant huntingtin protein. HD Immune's approach leverages antibody-mediated clearance of mutant huntingtin aggregates, potentially slowing or halting neurodegeneration. The company operates in the biologics space and is privately held, with no disclosed funding rounds or valuation. Given the high unmet need in HD and the limited therapeutic options, HD Immune's novel mechanism holds promise, though it remains in early preclinical or discovery stages based on available information. The company's progress is closely watched by the HD community, but significant development and regulatory milestones lie ahead.

Upcoming Catalysts (preview)

• Q4 2025In Vivo Proof-of-Concept Data in HD Mouse Models60% success
• Q2 2026IND-Enabling Studies Initiation40% success
• Q3 2026Series A Financing Round55% success